Solvemed showcases PuRe™ Pupillometer technology at premier neurocritical care conference, demonstrating breakthrough AI-powered medical device for ICU applications.
.png)
Solvemed's co-founders Hugo Chrost and Michal Wlodarski are proudly representing the company at the prestigious Neurocritical Care Society Annual Meeting in Phoenix, Arizona. This landmark neurocritical care event brings together over 2,000 critical care specialists, neurocritical care physicians, and pioneering AI-powered medical device companies from around the globe, all united by a singular vision: transforming intensive care units to be more efficient, accessible, and innovative.
At the heart of Solvemed's presentation is the PuRe™ Pupillometer, an AI-powered medical device specifically designed for neurocritical care and neurodiagnostics. This innovative Software as Medical Device (SaMD) leverages advanced artificial intelligence to deliver accurate and reliable pupillometry testing directly from healthcare professionals' smartphones, revolutionizing pupillometer technology for intensive care units.
The PuRe™ Pupillometer represents a significant advancement in neurodiagnostics, enabling intensive care unit practitioners to conduct comprehensive pupillometry assessments with enhanced precision and accessibility. This AI-powered pupillometer solution addresses the critical need for reliable neurodiagnostics tools in high-stakes neurocritical care environments.
This year's Neurocritical Care Society Annual Meeting theme, #BeyondTheHorizon, aligns with Solvemed's mission to advance neurocritical care through AI-powered medical devices innovation. The company envisions a future where intensive care units are fundamentally enhanced by pupillometry software solutions and digitalization, making advanced neurodiagnostics more accessible to healthcare providers worldwide.
Solvemed's commitment to this digital transformation is embodied in their smartphone-based pupillometer technology. By democratizing access to sophisticated neurodiagnostics assessment tools, the PuRe™ Pupillometer enables healthcare professionals to gain valuable insights into patients' neurological status without the need for expensive, bulky traditional pupillometry equipment.
The integration of AI-powered medical devices like the PuRe™ Pupillometer represents a significant advancement in patient care quality in intensive care units (ICUs). Healthcare professionals can now perform thorough neurodiagnostic assessments with pupillometry tools that are precise, reliable, intuitive, and easily accessible. Accurate and timely pupillary assessments are crucial in neurocritical care environments, where rapid decision-making can significantly influence patient outcomes. Anisocoria, defined as unequal pupil sizes, is a critical diagnostic indicator; recent studies demonstrate the substantial variability in diagnosing anisocoria depending on the measurement method and threshold definitions used. Quantitative pupillometry, such as that offered by devices like PuRe™, enhances accuracy and consistency in detecting this condition, thereby aiding clinicians in rapid and precise diagnostics and interventions (Saju et al., et al.).
Moreover, understanding and tracking neurological changes, including alterations in consciousness, are imperative for optimal patient management. Regular, systematic assessments using validated scales like the Glasgow Coma Scale and FOUR Score are critical for detecting subtle neurological changes promptly, facilitating early intervention, and improving patient outcomes (Hill et al., et al.). Continuous multimodal monitoring of neurological status, including vital signs, motor and sensory function, and cranial nerve responses, remains a cornerstone of effective neurocritical care, enabling healthcare professionals to recognize deterioration early and intervene decisively (Robba et al., et al.).
Solvemed's team is honored to participate in this prestigious gathering of neurocritical care leaders and innovators. The opportunity to present the PuRe™ Pupillometer alongside industry pioneers reinforces our commitment to advancing patient care through cutting-edge technology. We are excited to engage with healthcare professionals, share our clinical insights, and learn from the collective expertise of the neurocritical care community.
The enthusiastic reception of our AI-powered pupillometry solution at this conference validates our vision of making advanced neurodiagnostics accessible to healthcare providers worldwide. We look forward to continuing these meaningful conversations, fostering collaborations, and contributing to the evolution of neurocritical care that will ultimately benefit patients in intensive care units across the globe. This conference experience strengthens our dedication to pushing the boundaries of what's possible in neurocritical care technology and reaffirms our mission to transform patient outcomes through innovative medical devices.
Hill M, Moreda M, Navarro J, Mulkey M. Assessing patients with altered level of consciousness. Critical Care Nurse. 2023;43(4):58-65. https://doi.org/10.4037/ccn2023449
Saju C, Barnes A, Kuramatsu JB, Marshall JL, Obinata H, Puccio AM, et al. Describing anisocoria in neurocritically ill patients. American Journal of Critical Care. 2023;32(6):402-409. https://doi.org/10.4037/ajcc2023558
Robba C, Zanier ER, Lopez Soto C, Park S, Sonneville R, Helbolk R, et al. Mastering the brain in critical conditions: an update. Intensive Care Medicine Experimental. 2024;12:1. https://doi.org/10.1186/s40635-023-00587-3
A proven pioneer in medical technology and recognized expert in physiological signal analysis, Marek has played a pivotal role as Solvemed's CTO. His transition to the Board marks a strategic inflection point as the company scales its AI Pupillometry System toward broader clinical adoption.
